Comerica Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Comerica Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44	Closed	-$401	–	1310
2022 Q4	$401	Buy	+44	New	+$384	﹤0.01%	1435
2020 Q1	–	Sell	-23,669	Closed	-$232K	–	463
2019 Q4	$232K	Buy	+23,669	New	+$211K	0.02%	397
2016 Q3	–	Sell	-4,417	Closed	-$222K	–	374
2016 Q2	$222K	Sell	4,417 -191	-4%	-$10.2K	0.05%	317
2016 Q1	$247K	Buy	4,608 +334	+8%	+$19.6K	0.06%	289
2015 Q4	$281K	Sell	4,274 -2	-0%	-$124	0.07%	274
2015 Q3	$241K	Buy	4,276 +215	+5%	+$13.9K	0.07%	280
2015 Q2	$240K	Buy	4,061 +798	+24%	+$49.2K	0.06%	287
2015 Q1	$203K	Buy	+3,263	New	+$190K	0.05%	293

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Comerica Securities's TEVA Position: Q1 2023 in Review

Comerica Securities sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 44 shares — an estimated $401 sold.

Comerica Securities first reported a position in TEVA in Q1 2015 and held it in 8 quarters. The position peaked at $281K in Q4 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

Comerica Securities reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 44 Teva Pharmaceuticals shares in Q1 2023, an estimated $401.
Comerica Securities first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 8 quarters.
Comerica Securities's Teva Pharmaceuticals position peaked at $281K in Q4 2015.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.